Print
Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis
https://www.facingourrisk.org/research-clinical-trials/study/198/studying-the-medication-olaparib-given-with-radium-223-for-advanced-prostate-cancer-with-bone-metastasis
Clinicaltrials.gov identifier:
NCT03317392 (https://clinicaltrials.gov/show/NCT03317392)
People with castration-resistant prostate cancer with bone spread
Study Contact Information:
Contact: Rana R McKay 858-822-5354 or by email: [email protected]
About the Study
This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones.
This study is no longer recruiting patients
Type of Study
This is a randomized study with two separate treatment groups.
Participants are placed into one of two study groups by chance, and neither the participants nor the researchers choose the group into which the participants are placed.
- Group 1 participants will receive radium injection and oral olaparib.
- Group 2 participants will receive radium injection only.
The study allows crossover. Participants in Group 2 whose cancer gets worse will be allowed to switch to Group 1 and receive olaparib.
What the Study Involves
- The study involves up to 6 cycles of 28 days, for a total of 168 days. All participants will receive an injection of radium-223 into their vein, two times on day one, then again every 28 days.
- Group 1 participants will also receive olaparib orally two times daily for the entire 168 day treatment period.
- Group 2 participants will not receive olaparib, unless their cancer gets worse. Participants in Group 2 whose cancer gets worse will be allowed to switch over to Group 1 to receive olaparib.
- Participants will be followed for up to two years for side effects, quality of life, and progression of disease.
Study Sites
California
- San Diego, CA
UC San Diego Moores Cancer Center Recruiting
Contact: 858-822-5354 or by email: [email protected]
Lead researcher: Rana R. McKay, MD
- Sacramento, CA
University of California Davis Comprehensive Cancer Center
Contact: 916-734-3089
Lead researcher: Mamta Parikh, MD
Kansas
- Fairway, KS
University of Kansas Clinical Research Center
Contact: 913-588-3671 or by email: [email protected]
Lead researcher: Rahul A. Parikh, MD
- Kansas City, KS
University of Kansas Cancer Center
Contact: 913-588-3671 or by email: [email protected]
Lead researcher: Rahul A. Parikh, MD
- Overland Park, KS
University of Kansas Cancer Center
Contact: 913-588-3671 or by email: [email protected]
Lead researcher: Rahul A. Parikh, MD
- Westwood, KS
University of Kansas Hospital-Westwood Cancer Center
Contact: 913-588-3671 or by email: [email protected]
Lead researcher: Rahul A. Parikh, MD
Maryland
- Baltimore, MD
University of Maryland/Greenebaum Cancer Center
Contact: 800-888-8823
Lead researcher: Arif Hussain, MD
Missouri
- Creve Coeur, MO
Siteman Cancer Center at West County Hospital
Contact: 800-600-3606 or by email: [email protected]
Lead researcher: Hiram A. Gay, MD
- Kansas City, MO
University of Kansas Cancer Center - North
Contact: 913-588-3671 or by email: [email protected]
Lead researcher: Rahul A. Parikh, MD
- Lee's Summit, MO
University of Kansas Cancer Center - North
Contact: 913-588-3671 or by email: [email protected]
Lead researcher: Rahul A. Parikh, MD
- Saint Louis, MO
Washington University School of Medicine
Contact: 800-600-3606 or by email: [email protected]
Lead researcher: Hiram A. Gay, MD
- Saint Louis, MO
Siteman Cancer Center-South County
Contact: 800-600-3606 or by email: [email protected]
Lead researcher: Hiram A. Gay, MD
- Saint Peters, MO
Siteman Cancer Center at Saint Peters Hospital
Contact: 800-600-3606 or by email: [email protected]
Lead researcher: Hiram A. Gay, MD
New Jersey
- New Brunswick, NJ
Rutgers Cancer Institute of New Jersey
Contact: 732-235-7356
Lead researcher: Biren Saraiya, MD
Ohio
- Columbus, OH
Ohio State University Comprehensive Cancer Center
Contact: 800-293-5066 or by email: [email protected]
Lead researcher: Edmund Folefac, MD
Pennsylvania
- Pittsburgh, PA
University of Pittsburgh Cancer Institute (UPCI)
Contact: 412-647-8073
Lead researcher: Adam Olson, MD
Wisconsin
- Madison, WI
University of Wisconsin Carbone Cancer Center
Contact: 800-622-8922
Lead researcher: Christos Kyriakopoulos
This Study is Open To:
This study is no longer recruiting patients.
This Study is Not Open To:
This study is no longer recruiting patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.